Renal phospholipidosis possibly induced by ranolazine

Clinical Kidney Journal

Volumn 7, Issue 1, 2014, Pages 62-64

  Scheurle, Christoph ^a   Dämmrich, Maximilian ^b   Becker, Jan U ^b   Baumgärtel, Martin W ^a  

^a ST FRANZISKUS HOSPITAL   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

cationic amphiphilic drugs; myelin bodies; ranolazine; renal phospholipidosis; zebra bodies

Indexed keywords

CREATININE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; RANOLAZINE;

ACUTE HEART FAILURE; ACUTE ON CHRONIC LIVER FAILURE; AGED; ALBUMINURIA; ARTICLE; CASE REPORT; CAUCASIAN; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CYTOPLASM; DIASTOLIC DYSFUNCTION; DIURETIC THERAPY; DRUG INDUCED DISEASE; FOCAL GLOMERULOSCLEROSIS; GAMMOPATHY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HISTOLOGY; HUMAN; HYALINE DEGENERATION; KIDNEY AMYLOIDOSIS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY FUNCTION; LIPIDOSIS; MALE; MYELOMA; NEPHROSCLEROSIS; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RENAL REPLACEMENT THERAPY; RESTRICTIVE CARDIOMYOPATHY; ZEBRA BODY;

EID: 84893114823     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sft141     Document Type: Article

References (13)

1. DAgati VD, Fogo AB, Bruijn JA et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004; 43(2): 368-382
2. Bracamonte ER, Kowalewska J, Starr J et al. Iatrogenic phospholipidosis mimicking Fabry disease. Am J Kidney Dis 2006; 48(5): 844-850
3. Zarate YA, Hopkin RJ. Fabrys disease. Lancet 2008; 372: 1427-1435
4. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006; 5(4): 567-583
5. Reasor MJ, Kacew S. Drug-induced phospholipidosis: are there functional consequences? Exp Biol Med 2001; 226(9): 825-830
6. Halliwell WH. Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 1996; 25(1): 53-60
7. Terryn W, Cochat P, Froissart R et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice. Nephrol Dial Transplant 2013; 28(3): 505-517
8. Stratta P, Quaglia M, Messina M et al. The challenges of diagnosing Fabry disease. Am J Kidney Dis 2008; 51(5): 860-864
9. Waldek S, Manesh RP, Banikaemi B et al. Life expectancy and cause of death in males and females with Fabry disease: findings fromthe Fabry Registry. Genet Med 2009; 11(11): 790-796
10. Albay D, Adler SG, Philipose J et al. Chloroquine-induced lipidosismimicking Fabry disease. Mod Pathol 2004; 18(5): 733-738
11. Mller-Hocker J, Schmid H, Weiss M et al. Chloroquineinduced phospholipidosis of the kidney mimicking Fabrys disease: case report and review of the literature. Hum Pathol 2003; 34(3): 285-289
12. Pairach P, Cook WJ. Progressive renal insufficiency associated with renal phospholipidosis. Kidney Int 2008; 74: 1354-1357
13. Rubinow A, Skinner M, Cohen AS. Digoxin sensitivity in amyloid cardiomyopathy. Circulation 1981; 63(6): 1285-1288